Clinical Trial Update: Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study of intralesional M4N in patients with refractory head and neck cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• M4N

Snippet

Sponsor: Erimos Pharmaceuticals | Conditions: Head and Neck Neoplasms | Phase 1 | Status: COMPLETED